ClinicalTrials.gg
Not yet recruitingNCT07853716REFINE-CACUpdated Oct 2, 2026

REFINE-CAC Protocol: Risk Evaluation With AI-CPA + HCS For Patients IN Whom Calcium is confirmEd to Improve Coronary Artery Disease Care

An interventional study of Heartflow Analysis in CAD - Coronary Artery Disease, sponsored by HeartFlow, Inc.. Not yet recruiting at 1 site in United States. Open to participants aged 40 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by HeartFlow, Inc. · Not applicable, Interventional, and Prevention

How we know

Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
40 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Coronary Artery Disease by HeartFlow, Inc. — 4 open to participants now, 5 under way, none of them phase 3. Coronary Artery Disease · HeartFlow, Inc..

Started
2026
with 2 others
No phase
5 of 12
2 open now
Registered
12th of 12
by date

Among the 12 studies in Coronary Artery Disease by HeartFlow, Inc., this one is one of 3 that started in 2026, is one of 5 with no phase, and was the 12th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

4 of the 12 studies in Coronary Artery Disease by HeartFlow, Inc. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 40 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Coronary Artery Disease by HeartFlow, Inc., or all of them as a file.
02

Study summary

REFINE-CAC is a prospective, multi-center trial assessing the management of asymptomatic participants with CAC scores 1-299 Agatston units or incidental CAC findings on chest computed tomography (CT), all of whom will undergo CCTA and are blinded to the coronary anatomy (e.g., % stenosis). The trial includes a randomized, controlled pathway and a single arm, observational registry pathway.

Read the detailed description

The primary objective of the REFINE-CAC trial is to assess change in lipid lowering therapy over time in asymptomatic participants with coronary artery calcium (CAC) findings who will undergo a blinded coronary computed tomographic angiography (CCTA) and are randomly assigned to either the test arm or the usual care arm.

03

Conditions studied

  • CAD - Coronary Artery Disease

Keywords

  • CAD
  • AI-CPA
  • CCTA
  • CACS
  • CAC
  • Coronary Plaque
  • Incidental CAC
04

Who can participate

Ages eligible
40 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Calcium score between 1-299 between 3-6 months prior to Day 0 or incidental CAC findings on a chest CT between 3 to 6 months prior to Day 0
  2. Men ≥40 and ≤79, Women ≥45 and ≤79
  3. Patients who do not have symptoms suggestive of CAD
  4. Visible plaque on CCTA
  5. No other clinical CCTA subsequent to CAC findings but prior to screening
  6. No prior history of atherosclerotic cardiovascular disease (ASCVD)
  7. Acceptable CCTA quality per Heartflow acceptance criteria
  8. >45 mL/min per most recent measurement within 90 days
  9. Willingness to comply with all aspects of the protocol including research CCTAs, lab draws, medication adherence assessments, attending all study visits, and the ability to comply with prescribed medications
  10. For participants of (those who have not been surgically sterilized), a pregnancy test must be performed with negative results known within 7 days prior to randomization
  11. Ability to provide

Exclusion criteria

Exclusion Criteria:

  1. Symptoms suggestive of CAD (e.g. stable angina)
  2. On PCSK9 targeted therapy (e.g. evolocumab, alirocumab, inclisiran, or enlicitide)
  3. Reduced (LVEF) \<35%, if known
  4. Prior history of ASCVD
  5. Prior coronary artery bypass graft (CABG)
  6. Prior percutaneous coronary intervention (PCI)
  7. less than 2 years due to non-CV comorbidities
  8. Enrolled in an trial that involves a non-approved cardiac drug or device
  9. Previously evaluated with and/or in a trial which includes AI-CPA
  10. Any condition that might interfere with trial procedures or follow up visits
  11. LDL-C \<70 mg/dL at baseline lab draw
  12. Active chemotherapy and/or radiation
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • No intervention
    Usual Care Arm
  • Experimental
    Unblinded Test Arm

    Device: Heartflow Analysis

  • Other
    Unblinded Registry Arm

    Device: Heartflow Analysis

Interventions

  • DeviceHeartflow Analysis

    REFINE-CAC will provide Heartflow Analyses

06

What researchers measure

Primary outcomes

  1. Percentage of participants who initiate, intensify, cease, or de-escalate lipid lowering therapy (LLT)

    Time frame: Enrollment to 90 days

Secondary outcomes

  1. Percentage of participants who initiate, intensify, cease, or de-escalate lipid-lowering therapy (LLT)

    Time frame: Enrollment through end of study at 21 months

  2. Percentage of participants who initiate, intensify, cease, or de-escalate medication therapy

    Time frame: Enrollment through end of study at 21 months

  3. Time to initiation, intensification, cessation, or de-escalation of LLT

    Time frame: Enrollment through end of study at 21 months

  4. Percent of participants undergoing lipid testing

    Time frame: Enrollment through end of study at 21 months

  5. LDL-C changes

    Time frame: Enrollment through end of study at 21 months

  6. Changes in Plaque Volumes

    Time frame: Enrollment through end of study at 21 months

  7. Rates of referral to invasive coronary angiography and coronary revascularization

    Time frame: Enrollment through end of study at 21 months

  8. Percentage of participants classified as high adherence on the 8-item Morisky Medication Adherence Scale (MMAS-8)

    Evaluated using the 8-item MMAS-8 questionnaire. Total scores range from 0 to 8, where higher scores indicate better adherence. High adherence is defined as achieving a score of 8, medium adherence as 6 to \<8, and low adherence as \<6.

    Time frame: Enrollment through end of study at 21 months

07

Study locations

1 site
  • REFINE-CAC Trial Site
    New York, New York 10005, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jun 2029, 31 months later.

Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's planned 31 months is above that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2026
First posted
Oct 2, 2026
StartEst.
Nov 2026
Primary completionEst.
Jun 2029
CompletionEst.
Jun 2029
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07853716
Lead sponsor
HeartFlow, Inc.
Collaborators
Avania
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Nov 2026 (estimated)
Primary completion
Jun 2029 (estimated)
Completion
Jun 2029 (estimated)
Last update
Oct 2, 2026

Study contacts

Whitney Huey
Contact
whuey@heartflow.com
8774783569
Blair Holman
Contact
bholman@heartflow.com
8774783569

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion